Neotetrazolium chloride
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Neotetrazolium chloride
- Molecular weight
- 667.6
- Structure (SMILES)
These details could not be displayed.
- 2 2 5 5 tetraphenyl 3 3 p diphenylene ditetrazolium chloride
- 2 2 p diphenylene bis 3 5 diphenyl ditetrazolium chloride
- 2,2'-(P-DIPHENYLENE)-BIS(3,5-DIPHENYL)DITETRAZOLIUM CHLORIDE
- 2,2',5,5'-TETRAPHENYL-3,3'-(P-DIPHENYLENE)DITETRAZOLIUM CHLORIDE
- 2h tetrazolium 3 3 1 1 biphenyl 4 4 diylbis 2 5 diphenyl chloride 1 2
- 2H-TETRAZOLIUM, 3,3'-(1,1'-BIPHENYL)-4,4'-DIYLBIS(2,5-DIPHENYL-, CHLORIDE (1:2)
- 3 3 1 1 biphenyl 4 4 diylbis 2 5 diphenyl 2h tetrazolium dichloride
- 3 3 4 4 biphenylene bis 2 5 diphenyl 2h tetrazolium dichloride
- 3,3'-(1,1'-BIPHENYL)-4,4'-DIYLBIS(2,5-DIPHENYL-2H-TETRAZOLIUM) DICHLORIDE
- 3,3'-(4,4'-BIPHENYLENE)BIS(2,5-DIPHENYL-2H-TETRAZOLIUM) DICHLORIDE
- camrelizumab plus tp
- neo t
- Neo-t
- Neo-T
- neotetrazolium blue
- Neotetrazolium blue
- neotetrazolium chloride
- Neotetrazolium chloride
- NEOTETRAZOLIUM CHLORIDE [MI]
- neotetrazolium chloride mi
- nsc 27621
- NSC-27621
- ntc
- NTC
- tp
And 1 more, listed on the interactive page.
- CAS registry numbers
- 298-95-3
- ChEMBL ID
- CHEMBL313155
- InChIKey
- WYFYSTBFFDOVJW-UHFFFAOYSA-L
- PubChem compound IDs
- 2723605
- FDA ingredient codes (UNII)
- QL8L44VE6R
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ium
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
Open Targets indications
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- NCT05798533
- NCT05798546
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 69.18
- Calculated partition coefficient (ALogP)
- 6.4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 7
- Heavy atoms
- 48
- Molecular formula
- C38H28Cl2N8
- Monoisotopic mass
- 666.1813983
- Natural product
- No
- Recorded assays
- 6
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (13)
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
- Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
- Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
- Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
- Gait Training Combined With Behavioral Strategies for People With Stroke
- Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
- Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
- Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer
- Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
- Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
- Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
In development for (1)
- Neoplasm Phase 1